Viragen Inc said it will start anexpanded study of its alpha interferon topical ointment for thetreatment of genital herpes.    It said it will conduct a phase III study of two differentdosage forms of the treatment and compare it to a placebo, ornonmedicated substitute, in at least 154 men and women. Viragensaid study results are expected by October 1987.    Viragen said it is prepared to submit license applicationsfor the ointment in England, Canada, and West Germany, inaddition to the U.S., when the phase III study is completed. Reuter&#3;